Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
종목 코드 SLNO
회사 이름Soleno Therapeutics Inc
상장일Oct 23, 2014
설립일1999
CEODr. Anish Bhatnagar, M.D.
직원 수92
유형Ordinary Share
회계 연도 종료Oct 23
주소100 Marine Parkway, Suite 400
도시REDWOOD CITY
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호94065
전화16502138444
웹사이트https://soleno.life/
종목 코드 SLNO
상장일Oct 23, 2014
설립일1999
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음